, Volume 21, Issue 2, pp 135–137 | Cite as

Panitumumab in the Treatment of Metastatic Colorectal Cancer

Profile Report
  • Sheridan M. Hoy
  • Antona J. Wagstaff
Adis Profile Report

Approximately 655 000 deaths worldwide each year can be attributed to colorectal cancer.[4] The primary treatment option for patients with colorectal cancer is surgery;[5] however, approximately 50% of patients will subsequently develop metastases.[6,7] The prognosis for these patients is generally poor; median survival from diagnosis is 6–9 months[8] and the 5-year survival rate is <5%.[6] Nevertheless, quality of life, time to disease progression, and overall survival in patients with metastatic colorectal cancer can be improved with the use of chemotherapy.[6,7]

Tumor growth is dependent upon the activation of cell membrane receptors, which indirectly control adhesion, motility, and proliferation.[7] The epidermal growth factor receptor (EGFR), which is expressed on normal epithelial, glial, smooth muscle, and stromal cells[7,9,10] and is involved in the regulation of cellular differentiation and proliferation,[6] is overexpressed in 25–77% of colorectal cancers.[9,11] This...


Epidermal Growth Factor Receptor Irinotecan Cetuximab Metastatic Colorectal Cancer Epidermal Growth Factor Receptor Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Hoy SM, Wagstaff AJ. Panitumumab: in the treatment of metastatic colorectal cancer. Drugs 2006; 66(15): 2005–14PubMedCrossRefGoogle Scholar
  2. 2.
    Malik I. Panitumumab: a viewpoint by Imtiaz Malik. Drugs 2006; 66(15): 2015CrossRefGoogle Scholar
  3. 3.
    Ranson M. Panitumumab: a viewpoint by Malcolm Ranson. Drugs 2006; 66(15): 2015–6CrossRefGoogle Scholar
  4. 4.
    World Health Organization. Cancer [online]. Available from URL: [Accessed 2006 May 18]
  5. 5.
    Labianca RF, Beretta GD, Pessi MA. Colorectal cancer: disease management considerations. Drugs 2001; 61(12): 1751–64PubMedCrossRefGoogle Scholar
  6. 6.
    Jefford M, Zalcberg J. Recent advances in the systemic therapy of metastatic colorectal cancer. Am J Cancer 2005; 4(1): 15–34CrossRefGoogle Scholar
  7. 7.
    Coutinho AK, Rocha Lima CMS. Metastatic colorectal cancer: systemic treatment in the new millennium. Cancer Control 2003; 10(3): 224–38PubMedGoogle Scholar
  8. 8.
    Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000 Sep 2; 321(7260): 531–5PubMedCrossRefGoogle Scholar
  9. 9.
    Alekshun T, Garrett C. Targeted therapies in the treatment of colorectal cancers. Cancer Control 2005 Apr; 12(2): 105–10PubMedGoogle Scholar
  10. 10.
    Venook AP. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 2005; 103(12): 2435–46PubMedCrossRefGoogle Scholar
  11. 11.
    McWilliams RR, Erlichman C. Novel therapeutics in colorectal cancer. Dis Colon Rectum 2005; 48(8): 1632–50PubMedCrossRefGoogle Scholar
  12. 12.
    Ranson M. Technology evaluation: ABX-EGF, Abgenix/Amgen. Curr Opin Mol Ther 2003 Oct; 5(5): 541–6PubMedGoogle Scholar
  13. 13.
    Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004 Dec; 11(4): 689–708PubMedCrossRefGoogle Scholar
  14. 14.
    Veronese ML, O’Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 2004 Jun; 40(9): 1292–301PubMedCrossRefGoogle Scholar
  15. 15.
    Levene AP, Singh G, Palmieri C. Therapeutic monoclonal antibodies in oncology. J R Soc Med 2005; 98(4): 146–52PubMedCrossRefGoogle Scholar
  16. 16.
    Yang X-D, Jia X-C, Corvalan JRF, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17–23PubMedCrossRefGoogle Scholar
  17. 17.
    Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother 2006 Jan-Feb; 29(1): 1–9PubMedCrossRefGoogle Scholar
  18. 18.
    Peeters M, Van Custem E, Siena S, et al. A phase III, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) versus BSC alone in patients with metastatic colorectal cancer [abstract no. CP-1] plus oral presentation at 97th Annual Meeting of the American Association for Cancer Research; 2006 Apr 1-5; Washington, DCGoogle Scholar
  19. 19.
    Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥10% epidermal growth factor receptor (EGFr) [abstract no. 3548]. J Clin Oncol 2006; 24 (18 Suppl. Pt 1): 158s. Plus poster presented at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting; 2006 Jun 2–6; Atlanta (GA)Google Scholar
  20. 20.
    Hecht J, Mitchell E, Baranda J, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (<l–9%) or negative (<1 %) levels of epidermal growth factor receptor (EGFr) [abstract no. 3547]. J Clin Oncol 2006; 24 (18 Suppl. Pt 1): 157s. Plus poster presented at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting; 2006 Jun 2–6; Atlanta (GA)CrossRefGoogle Scholar
  21. 21.
    Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer [abstract no. 3520]. J Clin Oncol 2005; 23 (16 Suppl. Pt I): 251S. Plus poster presented at the 41st American Society of Clinical Oncology (ASCO) Annual Meeting; 2005 May 13–17; Orlando (FL)Google Scholar
  22. 22.
    Hecht J, Posey S, Tchekmedyian S, et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan or FOLFIRI for first-line treatment of metastatic colorectal cancer [abstract no. 237]. 3rd Annual Gastrointestinal Cancers Symposium; 2006 Jan 26–28; San Francisco (CA)Google Scholar
  23. 23.
    Amgen. Vectibix™ [panitumumab] prescribing information [online]. Available from URL: [Accessed 2006 Oct 3]

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Sheridan M. Hoy
    • 1
    • 2
  • Antona J. Wagstaff
    • 1
    • 2
  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthConshohockenUSA

Personalised recommendations